Risultati per: Trattamento della PA nella malattia renale cronica (MRC)

Senza DRG, i pazienti non hanno accesso a farmaci e monitoraggio

Senza DRG, i pazienti non hanno accesso a farmaci e monitoraggio

Neurologi: ‘si apre una nuova storia per i pazienti’

Circulation, Volume 150, Issue Suppl_1, Page A4147677-A4147677, November 12, 2024. Introduction:Elevated pulmonary vascular resistance (PVR) during exercise is a proposed marker of negative prognosis in patients with heart failure with preserved ejection fraction (HFpEF), however its pathophysiology is incompletely characterised. We investigate here the relative contribution to exercise-induced PVR on right ventricular (RV) functional and structural remodelling and pulmonary artery (PA) coupling during exercise in HFpEF patients.Methods:We included 67 consecutive patients from the Johns Hopkins HFpEF Clinic where supine bicycle exercise right heart catheterisation (RHC) was available. In agreement with previous studies, we defined 2 distinct subgroups: patients with elevated exercise-induced PVR (HFpEF-highPVR), including patients with PVR ≥ 1.74 WU at maximal effort and those without exercise-induced PVR (HFpEF-normalPVR) patients with PVR < 1.74 WU at maximal effort. Echocardiography and RV endomyocardial biopsy (EMB) data were analysed to assess cardiac structural and functional remodelling associated with HFpEF-highPVR.Results:From the total of 67 patients, 23 (34%) had elevated PVR at rest (PVR≥2 WU) of which 17 (74%) continued on to have exercise-induced PVR (PVR≥1.74 WU). From 44 (66%) patients without elevated PVR at rest, 4 (9.1%) further developed PVR at maximal exercise. (Figure1A). HFpEF-highPVR were older, had lower eGFR and higher NT-proBNP, than HFpEF-normalPVR. Maximal exercise tolerance was severely reduced in the HFpEF-highPVR group (14.0±13.7 vs 31.4±16.9 watts, P

Circulation, Volume 150, Issue Suppl_1, Page A4142415-A4142415, November 12, 2024. Background:Pulmonary embolism (PE) is a leading cause of cardiovascular death and preventable hospital mortality in the US. High-risk acute PE has a 30% mortality rate, despite new treatments like catheter-directed thrombolytics (CDT). CDT has shown to improve right ventricle/left ventricle (RV/LV) diameter ratio compared to anticoagulation alone, but the optimal t-PA dose is uncertain. Traditional dosing is 10-24 mg over 12-24 hours, but clinical trials have showed similar RV/LV diameter ratio reductions with lower doses and shorter infusions. No prospective data has shown a mortality benefit.Hypothesis:Higher t-PA doses will improve in-hospital mortality, length of stay (LOS), pulmonary artery (PA) pressure reduction, and cardiac biomarker reduction in patients receiving CDT for acute PE.Methods:We retrospectively analyzed patients who presented with PE and underwent CDT at a single center, tertiary hospital. Patients were stratified by t-PA dose (

Colpito almeno il 7% italiani, solo il 10% dei pazienti lo sa

Iss, “servono di bimbi sani o con sindrome di Rett fino a 6 mesi”

Iss, “servono di bimbi sani o con sindrome di Rett fino a 6 mesi”

Bloccano neurodegenerazione e potenziano terapia, test sui topi